Glycopyrrolate (injection): Difference between revisions
Shanshan Cen (talk | contribs) No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag={{SC}} | |authorTag={{SC}} | ||
|aOrAn= | |genericName=Glycoparrolate | ||
|aOrAn=an | |||
|drugClass=[[anticholinergic]] ([[antimuscarinic]]) agents | |||
|indicationType=treatment | |indicationType=treatment | ||
|adverseReactions=[[flushing]], [[constipation]], and [[vomiting]] | |||
|adverseReactions= | |||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> | ||
Line 323: | Line 324: | ||
<!--Brand Names--> | <!--Brand Names--> | ||
|brandNames=* GLYCOPYRROLATE ®<ref>{{Cite web | title =GLYCOPYRROLATE- glycopyrrolate injection, solution | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62267afe-1a73-4623-984e-646db590ec5b }}</ref> | |brandNames=* GLYCOPYRROLATE ®<ref>{{Cite web | title =GLYCOPYRROLATE- glycopyrrolate injection, solution | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62267afe-1a73-4623-984e-646db590ec5b }}</ref> | ||
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref> | |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref> | ||
Revision as of 18:17, 15 May 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Glycopyrrolate (injection) is an anticholinergic (antimuscarinic) agents that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include flushing, constipation, and vomiting.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
- Dosing Information
- Dosage
Condition2
- Dosing Information
- Dosage
Condition3
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Glycopyrrolate (injection) in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Glycopyrrolate (injection) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Glycopyrrolate (injection) in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Glycopyrrolate (injection) in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Glycopyrrolate (injection) in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Glycopyrrolate (injection) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Glycopyrrolate (injection) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Glycopyrrolate (injection) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Glycopyrrolate (injection) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Glycopyrrolate (injection) with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Glycopyrrolate (injection) with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Glycopyrrolate (injection) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Glycopyrrolate (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Glycopyrrolate (injection) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Glycopyrrolate (injection) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Glycopyrrolate (injection) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Glycopyrrolate (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Glycopyrrolate (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Glycopyrrolate (injection) in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Glycopyrrolate (injection) in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Glycopyrrolate (injection) in the drug label.
Pharmacology
There is limited information regarding Glycopyrrolate (injection) Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Glycopyrrolate (injection) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Glycopyrrolate (injection) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Glycopyrrolate (injection) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Glycopyrrolate (injection) in the drug label.
How Supplied
Storage
There is limited information regarding Glycopyrrolate (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Glycopyrrolate (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Glycopyrrolate (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Glycopyrrolate (injection) in the drug label.
Precautions with Alcohol
- Alcohol-Glycopyrrolate (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- GLYCOPYRROLATE ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "GLYCOPYRROLATE- glycopyrrolate injection, solution".
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Glycopyrrolate (injection) |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}} |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Glycopyrrolate (injection) |Label Name=Glycopyrrolate (injection)11.png
}}
{{#subobject:
|Label Page=Glycopyrrolate (injection) |Label Name=Glycopyrrolate (injection)11.png
}}